(RTTNews) - Moderna (MRNA) posted a third-quarter net loss of $200 million compared to net income of $13 million, last year. Loss per share was $0.51 compared to profit of $0.03. Analysts on average expected the company to report a loss per share of $2.18, for the quarter. Analysts' estimates typically exclude special items.
Net product sales were $973 million compared to $1.82 billion, prior year. Total revenue declined to $1.02 billion from $1.86 billion. Total revenue declined 45% primarily driven by a 47%, decrease in net product sales, mainly due to lower COVID vaccine sales.
For 2025, the company now expects total revenue in a range of $1.6 - $2.0 billion, narrowed from previous guidance range of $1.5 - $2.2 billion. The company projects fourth quarter revenue in a range of $0.3 - $0.7 billion.
The company's cash, cash equivalents and investments as of September 30, 2025, were $6.6 billion.
Shares of Moderna are up 9% in pre-market trade on Thursday. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
